Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 126, Issue 11, Pages 4076-4087Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI88410
Keywords
-
Categories
Funding
- American Cancer Society [RGS-10-124-01-CCE]
- NIH [U01-DK085570, U19-A1068021, CA106348]
- National Cancer Institute (NCI) [P30CA047904]
Ask authors/readers for more resources
Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is no FDA-approved agent for the prevention or treatment of radiation-induced intestinal injury. In this study, we have shown that PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration. PD treatment also enhanced LGR5(+) stem cell survival and regeneration after radiation. PD was an on-target inhibitor of RB phosphorylation and blocked VS transition in the intestinal crypts. PD treatment strongly but reversibly inhibited radiation-induced p53 activation, which blocked p53-upregulated modulator of apoptosis-dependent (PUMA-dependent) apoptosis without affecting p21-dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining. Further, deletion of PUMA synergized with PD treatment for even greater intestinal radioprotection. Our results demonstrate that the cell cycle critically regulates the DNA damage response and survival of intestinal stem cells and support the concept that pharmacological quiescence is a potentially highly effective and selective strategy for intestinal radioprotection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available